Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 pandemic. Our wo...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic and save lives....
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news
Started Early, Drug Combo Eases Fatigue of Rheumatoid Arthritis: Study
FRIDAY, June 26, 2020 -- Early and intensive treatment with methotrexate and prednisone can ease fatigue in people with rheumatoid arthritis (RA), according to a new study.
RA causes chronically inflamed joints and that inflammation can lead to... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 26, 2020 Category: General Medicine Source Type: news
COVID - 19 Hospitalization Up With Prednisone in Rheumatic Disease
No correlation seen for DMARD alone or in combination with biologics, Janus Kinase inhibitors, NSAIDs (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - June 23, 2020 Category: Respiratory Medicine Tags: Family Medicine, Infections, Internal Medicine, Critical Care, Emergency Medicine, Nursing, Pharmacy, Pulmonology, Rheumatology, Journal, Source Type: news
COVID-19 Hospitalization Up With Prednisone in Rheumatic Disease
TUESDAY, June 23, 2020 -- For patients with rheumatic disease with COVID-19, glucocorticoids are associated with increased odds of hospitalization, according to a study published in the July issue of the Annals of Rheumatic Diseases.
Milena... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 23, 2020 Category: Pharmaceuticals Source Type: news
What Does Prednisone Do to Your Body?
Title: What Does Prednisone Do to Your Body?Category: MedicationsCreated: 6/23/2020 12:00:00 AMLast Editorial Review: 6/23/2020 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - June 23, 2020 Category: Drugs & Pharmacology Source Type: news
Roche ’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints
Basel, 19 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) and whose tumours had PTEN loss. In this patient group, ipatasertib in combination with abiraterone and prednisone/prednisolone provided a statistically significant reduction in the risk of disease worsening or death, compared to current standard of care (abiraterone and prednisone/prednisolone) plus placebo. The other co-primary endpoint of rPFS in the overall st...
Source: Roche Investor Update - June 19, 2020 Category: Pharmaceuticals Source Type: news
Roche ’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints
·Phase III IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone compared to current standard-of-care (abiraterone and prednisone/prednisolone alone) plus placebo met its co-primary endpoint of radiographic progression free survival (rPFS) in patients with PTEN loss tumoursBasel, 19 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) and whose tumours had PTEN los...
Source: Roche Media News - June 19, 2020 Category: Pharmaceuticals Source Type: news
Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, NJ, June 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomized Phase 3 study investigating subcutaneous daratumumab[i] in the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare and potentially fatal disease.[1],[2] The data demonstrated subcutaneous daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) resulted in a higher hematologic complete response rate (CR), (53 percent vs. 18 percent [P<0.0001]), compared to CyBorD. Additionally, treatment with D-CyBorD delayed the time ...
Source: Johnson and Johnson - June 15, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
TNF Inhibitors May Dampen COVID-19 Severity TNF Inhibitors May Dampen COVID-19 Severity
Patients on a TNF inhibitor when contracting COVID-19 were less likely to require hospitalization. Conversely, patients on ≥ 10 mg of prednisone daily when infected were more likely to be hospitalized.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - May 21, 2020 Category: Rheumatology Tags: Rheumatology News Source Type: news
Janssen Announces Submission to U.S. FDA for New DARZALEX ® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “While we contin...
Source: Johnson and Johnson - February 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet needs continue...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Anifrolumab Benefits Seen in Second Lupus RCT Analysis Anifrolumab Benefits Seen in Second Lupus RCT Analysis
The monoclonal anifrolumab improved BICLA responses, reduced use of prednisone, and improved skin disease in patients with SLE, particularly those with high type 1 interferon gene signatures.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 23, 2019 Category: Consumer Health News Tags: Rheumatology News Source Type: news
University of Cincinnati finds new option for liver transplant patients
(University of Cincinnati) Budesonide, a drug commonly used to treat Crohn's Disease, may offer fewer side effects and work at least as well as prednisone as an anti-organ rejection medication in liver transplant patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 8, 2019 Category: International Medicine & Public Health Source Type: news
Study Finds Those With Asthma Should Avoid High-Dose Steroids
BOSTON (CBS)- A warning for people with asthma. A new study finds some asthmatics are taking harmful doses of steroids that could be putting their health at risk.
Oral steroids, like prednisone, reduce inflammation and are often used to ease the breathing of patients in the throes of an asthma attack. But prolonged or excessive doses can put patients at higher risk for diabetes, osteoporosis and hormonal abnormalities.
Researchers in the Netherlands studied more than two thousand patients with severe asthma who were on high doses of inhaled steroids and found that almost a third of them were also taking harmfully high ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - October 2, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Healthwatch Asthma Dr. Mallika Marshall Health Watch oral steroids Source Type: news
